Avanir Pharmaceuticals Rating Increased to Neutral at Zacks (AVNR)
Avanir Pharmaceuticals (NASDAQ:AVNR) was upgraded by Zacks from an “underperform” rating to a “neutral” rating in a note issued to investors on Thursday, American Banking News.com reports. The firm currently has a $3.20 target price on the stock. Zacks‘ price target indicates a potential upside of 0.95% from the stock’s previous close.
AVNR has been the subject of a number of other recent research reports. Analysts at Summer Street cut their price target on shares of Avanir Pharmaceuticals to $10.00 in a research note to investors on Wednesday, December 11th. They now have a “buy” rating on the stock. Analysts at Mizuho downgraded shares of Avanir Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, December 11th. They now have a $5.00 price target on the stock, down previously from $11.00. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $7.95.
Avanir Pharmaceuticals (NASDAQ:AVNR) last posted its quarterly earnings results on Tuesday, December 10th. The company reported ($0.10) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.02. The company had revenue of $21.70 million for the quarter, compared to the consensus estimate of $21.86 million. During the same quarter in the prior year, the company posted ($0.09) earnings per share. The company’s quarterly revenue was up 60.7% on a year-over-year basis.
AVANIR Pharmaceuticals, Inc (NASDAQ:AVNR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.